Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management
Round 1
Reviewer 1 Report
The manuscript by Wang et al. entitled “Immune checkpoint inhibitors associated thrombosis: Incidence, risk factors, and management”reviewed the current literature on the incidence, risk factors, and management of thrombosis in patients with cancer receiving ICIs. Overall the the paper is well-written, but there are still some suggestions to improve the quality of the manuscript.
1. It would be better for the readers to understand if there are some summary figures in the paper.
2. The reference style should be consistent.
Author Response
1. It would be better for the readers to understand if there are some summary figures in the paper.
Response: We have added Figure 1.
2. The reference style should be consistent.
Response: We have double-checked the reference style to ensure consistency. Please note that there are multiple papers with only one page listed because they are either conference abstracts or online open-access papers where only one page is provided for citation.
Reviewer 2 Report
The review is interesting and it is up to date. However, there is a need to include a figure describing the mechanism of Immune Check-point Inhibitor action for more clarity.
Author Response
Point: The review is interesting and it is up to date. However, there is a need to include a figure describing the mechanism of Immune Check-point Inhibitor action for more clarity.
Response: We have added Figure 1.
Reviewer 3 Report
The authors present a comprehensive overview of the currently available literature on the incidence, risk factors, and management of thrombosis in patients with cancer receiving immune check-point inhibitors. The author team has summarized the most recent and relevant papers on the subject. Although there are several typos and the narrative is a kind of fragmentary, I just abide by scientific soundness. The text is well written and very easy to read and follow it. I would like to offer the following minor points for consideration by the authors towards the improvement of the manuscript:
- My biggest criticism is that authors published a review on the same topic using similar data in similar tables. (Wang TF, Khorana AA, Carrier M. Thrombotic Complications Associated with Immune Checkpoint Inhibitors. Cancers (Basel). 2021;13(18):4606. Published 2021 Sep 14. doi:10.3390/cancers13184606
-There are a number of grammatical/spelling errors which need correcting. Some examples include:
-P1 Line 11: Please correct “ Cancer is associated with a siginficantly increaed risk of venous thromboembolism compared to non-cancer patients
-P1 Line 20: Please correct “ cancer-associated thrombosis”
-P5 Line 243: Please correct “caner-associated thrombosis”
Author Response
Point 1: My biggest criticism is that authors published a review on the same topic using similar data in similar tables. (Wang TF, Khorana AA, Carrier M. Thrombotic Complications Associated with Immune Checkpoint Inhibitors. Cancers (Basel). 2021;13(18):4606. Published 2021 Sep 14. doi:10.3390/cancers13184606
Response: Thank you for taking notice of our prior review. Compared to our last review, we have made major updates including a study on early CRP dynamics in the prediction of VTE in patients receiving ICIs and other cohort studies. Three out of the 4 tables (Tables 1, 3, and 4) are brand new in this paper. As for Table 2 (the incidence of thrombosis), although it might appear to be somewhat similar at the first glance, it had also been updated to include newer studies and items not included in the prior review. We also added a new figure (Figure 1) now with the revision to address other reviewers’ comments. To ensure the completeness of the review, we do need to include all the previously published studies included in our prior review. Overall, we feel that this review provides much updated information not available in the previous review, which showed the rapidly evolving data in this field and can be helpful for practicing clinicians.
Point 2: There are a number of grammatical/spelling errors which need correcting. Some examples include:
-P1 Line 11: Please correct “ Cancer is associated with a siginficantly increaed risk of venous thromboembolism compared to non-cancer patients
-P1 Line 20: Please correct “ cancer-associated thrombosis”
-P5 Line 243: Please correct “caner-associated thrombosis”
Response: We sincerely apologized for the oversight. All typos had been corrected. We've reviewed the full article again in detail to ensure no other typos.
